Charpentier G1Genès NVaur LClerson PAmar JGuéret PCambou JP.

ABSTRACT:

AIMS:

To assess hypertension management and blood pressure control in patients with type 2 diabetes in France.

DESIGN:

A cross sectional study was conducted in a representative sample of 410 diabetologists. The first 8 patients with type 2 diabetes, treated with oral antidiabetic agents and/or insulin, received at practitioner’s office were included. Cardiovascular risk factors, antihypertensive drugs, cardiovascular history were reported. BP was measured. Patients considered as hypertensive by his practitioner and receiving antihypertensive drugs were considered as hypertensives. Controlled hypertension was defined as a blood pressure < 140/80 mmHg. Uncontrolled hypertension was defined as blood pressure > or = 140/80 mmHg.

RESULTS:

4,930 diabetics were included in the study. Of them 3,085 (63%) patients were hypertensives. They were markedly older, overweight and reported most frequently complications. Only 723 (23%) patients presented with controlled hypertension. 40% of hypertensives were under monotherapy, 36% received 2 antihypertensive treatments and 24% received 3 treatments or more. ACE-inhibitors (49%), diuretics (41%), beta-blockers (35%), calcium channel blockers (33%), angiotensin II antagonists (19%) were the most commonly prescribed agents. Apart from hypertension, the main risk factors associated with each kind of prescription was micro or macroalbuminuria for ACE-I (OR = 1.5), coronary artery disease for beta-blockers and calcium channel blockers (OR = 3.8 and 2.5 respectively), and age for diuretics and angiotensin II antagonists (OR = 1.05 and 1.03).

CONCLUSION:

This study conducted in a representative sample of french diabetologists indicated that despite the large use of antihypertensive treatments only 23% of hypertensive diabetics were well controlled. Due to the high CV risk of these patients, hypertension management is of major importance.

Suscribe to our newsletter

By clicking on the link below, you will be redirected to Youtube. Third-party cookies may then be installed on your browser. These cookies are not implemented directly by the Soladis Clinical Studies site but by the site to which you connect.
Important: these cookies are subject to their own privacy policies and are in no way the responsibility of Soladis.
You can view Youtube's cookie policy by clicking on the following link: Google – Privacy & terms

  Follow Soladis on Youtube

By clicking on the link below, you will be redirected to LinkedIn. Third-party cookies may then be installed on your browser. These cookies are not implemented directly by the Soladis Clinical Studies site but by the social network site to which you connect.
These cookies are subject to their own privacy policies and are in no way the responsibility of Soladis.
You can view LinkedIn's cookie policy by clicking on the following link :  LinkedIn – Cookie Policy

Follow Soladis on LinkedIn

En cliquant sur le lien ci-dessous, vous allez être redirigé vers Youtube. Des cookies tiers peuvent alors être installés sur votre navigateur. Ces cookies ne sont pas implémentés directement par le site Soladis Clinical Studies mais par le site auquel vous vous connectez.
Important : ces cookies sont soumis à leurs propres politiques de confidentialité et ne relèvent en aucun cas de la responsabilité de Soladis.
Vous pouvez consulter la politique de Youtube en matière de cookies en cliquant sur le lien suivant : Google – Règles de confidentialité et conditions d’utilisation

  Suivre Soladis sur Youtube

En cliquant sur le lien ci-dessous, vous allez être redirigé vers LinkedIn. Des cookies tiers peuvent alors être installés sur votre navigateur. Ces cookies ne sont pas implémentés directement par le site Soladis Clinical Studies mais par le site de réseau social auquel vous vous connectez.
Ces cookies sont soumis à leurs propres politiques de confidentialité et ne relèvent en aucun cas de la responsabilité de Soladis.
Vous pouvez consulter la politique de LinkedIn en matière de cookies en cliquant sur le lien suivant : LinkedIn – Politique relative aux cookies

  Suivre Soladis sur LinkedIn